Corporate GovernanceJul 24, 2026, 06:07 AM
Outlook Therapeutics Grants Options, Potential Bonuses to CEO, CFO
AI Summary
Outlook Therapeutics, Inc. announced that its Compensation Committee approved stock option grants and potential cash bonuses for its Chief Executive Officer, Robert C. Jahr, and Chief Financial Officer, Lawrence A. Kenyon. Mr. Jahr received 100,000 options and Mr. Kenyon received 210,078 options, both with an exercise price of $1.4304 per share, vesting on July 21, 2027. Additionally, Mr. Jahr was awarded a potential cash bonus of $420,000 and Mr. Kenyon $200,000, contingent on FDA approval of ONS-5010 (bevacizumab-vikg) by July 31, 2026. These awards recognize their contributions to advancing the Biologics License Application for ONS-5010.
Key Highlights
- CEO Robert C. Jahr received 100,000 stock options.
- CFO Lawrence A. Kenyon received 210,078 stock options.
- Stock options have an exercise price of $1.4304 per share.
- Options vest on July 21, 2027, subject to continued service.
- CEO Jahr awarded potential cash bonus of $420,000.
- CFO Kenyon awarded potential cash bonus of $200,000.
- Cash bonuses are contingent on FDA approval of ONS-5010 by July 31, 2026.
Price Impact
More from OTLK